Hemato Oncology Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Leukemia is the fastest growing sector, North America is the largest market

The Global Hemato Oncology Testing Market is set for significant expansion, projected to grow from USD 3.21 Billion in 2025 to USD 5.37 Billion by 2031, achieving an 8.95% CAGR. This market centers on diagnostic procedures and assays used for identifying, predicting the course of, and monitoring hematologic malignancies, including leukemia, lymphoma, and myeloma. The primary drivers are the increasing global incidence of blood cancers and an aging population more susceptible to these conditions, distinct from evolving market trends like AI integration. For instance, the American Cancer Society estimated 192,070 combined diagnoses of leukemia, lymphoma, or myeloma in the U.S. in 2025. Despite this strong demand, a key obstacle is the high capital expenditure for advanced genomic testing instruments and complex reimbursement policies, which limit access to vital diagnostic services across many healthcare systems.

Market Drivers

Market growth is primarily propelled by advancements in Next-Generation Sequencing (NGS) and molecular diagnostics, which are fundamentally transforming the clinical management of hematologic malignancies. These technologies enable precise identification of genetic mutations and chromosomal abnormalities, such as BCR-ABL or FLT3, crucial for diagnosis and selecting targeted therapies. The move towards precision oncology has accelerated the adoption of high-throughput sequencing panels, offering faster results and higher sensitivity than traditional cytogenetics.

This technological momentum is evident in the financial performance of innovators like Tempus AI, which reported a 115.3% year-over-year increase in genomics revenue to $241.8 million in Q2 2025, driven by rising oncology testing volumes. Additionally, the escalating prevalence of hematologic malignancies, like the approximately 280,000 individuals living with blood cancer in the UK as reported by Blood Cancer UK in February 2025, necessitates widespread testing for early detection and disease monitoring. This substantial patient pool ensures sustained demand for initial diagnostic workups and recurring minimal residual disease testing, supported by major diagnostic corporations like Illumina, which generated $4.3 billion in fiscal year revenue for 2024, highlighting the vast commercial scale of the genomic testing infrastructure.

Market Challenges

A significant impediment to the expansion of the Global Hemato Oncology Testing Market is the substantial capital expenditure required for advanced genomic testing instruments. Laboratories and healthcare institutions face considerable financial burdens in acquiring these complex diagnostic platforms, which also demand extensive infrastructure and specialized maintenance. This high entry barrier restricts the adoption of genomic profiling capabilities mainly to well-funded academic centers and large reference laboratories, thereby excluding smaller regional hospitals and community clinics.

Consequently, a bottleneck in equipment procurement arises, as budget-constrained facilities are unable to invest in this crucial technology despite its clinical value. This financial constraint directly limits local testing volumes, often forcing healthcare providers to outsource samples and introducing logistical delays. The inability to widely deploy these instruments stands in stark contrast to the urgent clinical demand driven by the severity of hematologic malignancies; the American Cancer Society projected 56,110 U.S. deaths from leukemia, lymphoma, and myeloma in 2025, underscoring the critical need for accessible testing currently hindered by prohibitive equipment costs.

Market Trends

The post-treatment surveillance landscape for hematologic malignancies is rapidly being transformed by the accelerated adoption of liquid biopsy for Minimal Residual Disease (MRD) monitoring. This trend signifies a fundamental shift from invasive bone marrow aspirates to highly sensitive, peripheral blood-based testing, allowing for frequent, real-time tracking of leukemic clones. Clinicians are increasingly utilizing these non-invasive assays to detect sub-clinical relapse earlier than standard methods, facilitating timely therapeutic interventions.

The commercial success of this approach is demonstrated by Adaptive Biotechnologies, which reported a 52% year-over-year growth in MRD revenue to $37.5 million in Q3 2024, driven by the expanding use of its clonoSEQ assay for lymphoid cancers. Concurrently, the market is experiencing strategic consolidation to broaden molecular diagnostic portfolios, with major reference laboratories actively acquiring specialized genomic assets to create comprehensive "one-stop" oncology testing hubs. This strategy allows large providers to integrate niche, high-complexity assays, such as proprietary genetic panels and exome sequencing, into their existing service infrastructure, thus capturing a larger share of the diagnostic workflow. A notable example is Labcorp's April 2024 agreement to acquire select testing assets from Invitae, a transaction expected to generate approximately $275 million to $300 million in annual revenue, significantly enhancing its capabilities in oncology and rare disease diagnostics.

Key Market Players

• F. Hoffmann-La Roche Ltd
• EntroGen, Inc.
• Qiagen N.V.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Amoy Diagnostics Co. Ltd.
• ASURAGEN, INC
• ArcherDX, Inc

Report Scope

In this report, the Global Hemato Oncology Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemato Oncology Testing Market, by Cancer Type:

• Leukemia
• Lymphoma
• Myeloproliferative Neoplasms
• Other Cancers

Hemato Oncology Testing Market, by Product:

• Assay Kits and Reagents
• Services

Hemato Oncology Testing Market, by Technology:

• PCR
• IHC
• NGS
• Cytogenetics
• Other

Hemato Oncology Testing Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemato Oncology Testing Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.